Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Relapsing Remitting Multiple Sclerosis Patients between 18-55 years of age Diagnosis of MS, according to the revised McDonald 2010 EDSS score of 0-6.0 inclusive Documented at least one relapse within the past 12 months or at least one Gd-enhanced lesion on the brain MRI detected within 3 months prior to screening date Gd-enhanced lesion on screening MRI (if MRI not used to meet screening above) Female patients of childbearing potential will be expected to be on appropriate contraception (hormonal or barrier method of birth control; abstinence) from time of consent until 6 weeks after treatment discontinuation. (the repeated administration of gadolinium and MRI are not recommended during pregnancy). NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal Females of childbearing potential must have a negative urine pregnancy test prior to every MRI scan/ within 7 days prior to being registered for protocol therapy Must give written informed consent and authorize the release and use of protected health information, as required by local law Able and willing to undergo blood, saliva and urine sampling at regular intervals as defined by the protocol Able and willing to receive Gadolinium enhanced MRI's at regular intervals as defined by the protocol  Pregnant or breastfeeding or unwilling to use contraception Treatment with immunosuppressive, immunomodulatory or experimental treatments within the last 6 months of enrolment in the study, but excluding pulsed intravenous or oral steroids for treatment of MS relapse No pulsed intravenous or oral steroids in the 30 days preceding the baseline assessment Patients presenting with medical disorder deemed severe or unstable by the CI such as poorly controlled diabetes or arterial hypertension, severe cardiac insufficiency, unstable ischemic heart disease, abnormal liver function tests (>2.5 times ULN) and abnormal complete blood count (in particular leukopenia, as defined by a lymphocyte count <500, neutrophil <1.5 or platelet count < 100, or thrombocytopenia < 1.5 LLN), or any medical condition which, in the opinion of the chief investigator, would pose additional risk to the patient Presence of human immunodeficiency virus antibodies Patients receiving proton pump inhibitors (e.g. omeprazole/esomeprazole) Patients with active hepatitis B or/and C with liver function tests >2.5 times ULN Exposure to any other investigational drug within 30 days of enrolment in the study Prior history of malignancy unless an exception is granted by the Chief Investigator History of uncontrolled drug or alcohol abuse within 6 months prior to enrolment into the study